Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment

NCT02259855 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Insufficiency

Interventions

DRUG: Tipranavir
DRUG: Ritonavir
DRUG: Pegylated interferon
DRUG: Ribavirin

Sponsor

Boehringer Ingelheim